See more : Net-Digital AG (VRL.DE) Income Statement Analysis – Financial Results
Complete financial analysis of SOPHiA GENETICS SA (SOPH) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of SOPHiA GENETICS SA, a leading company in the Medical – Healthcare Information Services industry within the Healthcare sector.
You may be interested
- Labrador Iron Ore Royalty Corporation (LIFZF) Income Statement Analysis – Financial Results
- IHI Corporation (IHICY) Income Statement Analysis – Financial Results
- Kemp and Company Limited (KEMP.BO) Income Statement Analysis – Financial Results
- Chord Energy Corporation (CHRD) Income Statement Analysis – Financial Results
- Tianjin Ruixin Technology Co.,Ltd (300828.SZ) Income Statement Analysis – Financial Results
SOPHiA GENETICS SA (SOPH)
Industry: Medical - Healthcare Information Services
Sector: Healthcare
Website: https://www.sophiagenetics.com
About SOPHiA GENETICS SA
SOPHiA GENETICS SA operates as a healthcare technology company. The company offers SOPHiA DDM platform, a cloud-based software-as-a-service platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, products, and services are used by hospital, laboratory, and biopharma worldwide. SOPHiA GENETICS SA was incorporated in 2011 and is headquartered in Saint-Sulpice, Switzerland.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 62.37M | 47.56M | 40.45M | 28.40M | 25.36M |
| Cost of Revenue | 19.46M | 16.31M | 15.23M | 10.71M | 7.53M |
| Gross Profit | 42.91M | 31.25M | 25.22M | 17.69M | 17.83M |
| Gross Profit Ratio | 68.80% | 65.71% | 62.35% | 62.29% | 70.30% |
| Research & Development | 36.97M | 35.37M | 26.58M | 18.59M | 15.02M |
| General & Administrative | 53.30M | 55.82M | 41.51M | 18.97M | 15.67M |
| Selling & Marketing | 28.42M | 28.27M | 28.74M | 17.43M | 19.41M |
| SG&A | 81.72M | 84.08M | 70.24M | 36.40M | 35.08M |
| Other Expenses | -954.00K | -377.00K | -108.00K | -129.00K | 16.00K |
| Operating Expenses | 117.74M | 119.08M | 96.71M | 54.86M | 50.12M |
| Cost & Expenses | 137.20M | 135.38M | 111.94M | 65.57M | 57.65M |
| Interest Income | 4.55M | 1.32M | 20.00K | 96.00K | 86.00K |
| Interest Expense | 588.00K | 639.00K | 658.00K | 840.00K | 976.00K |
| Depreciation & Amortization | 8.34M | 5.57M | 3.61M | 2.39M | 1.91M |
| EBITDA | -70.70M | -82.67M | -70.84M | -38.76M | -30.74M |
| EBITDA Ratio | -113.35% | -172.94% | -167.76% | -122.11% | -119.42% |
| Operating Income | -74.83M | -87.82M | -71.49M | -37.17M | -32.29M |
| Operating Income Ratio | -119.97% | -184.66% | -176.73% | -130.86% | -127.30% |
| Total Other Income/Expenses | -3.67M | 238.00K | -2.02M | -3.84M | -1.34M |
| Income Before Tax | -78.50M | -87.59M | -73.51M | -41.23M | -33.63M |
| Income Before Tax Ratio | -125.85% | -184.16% | -181.72% | -145.16% | -132.60% |
| Income Tax Expense | 486.00K | -136.00K | 168.00K | -1.89M | 162.00K |
| Net Income | -78.98M | -87.45M | -73.68M | -39.34M | -33.79M |
| Net Income Ratio | -126.63% | -183.87% | -182.14% | -138.52% | -133.23% |
| EPS | -1.22 | -1.36 | -1.15 | -0.62 | -0.53 |
| EPS Diluted | -1.22 | -1.36 | -1.15 | -0.62 | -0.53 |
| Weighted Avg Shares Out | 64.75M | 64.10M | 63.86M | 63.86M | 63.86M |
| Weighted Avg Shares Out (Dil) | 64.75M | 64.10M | 63.86M | 63.86M | 63.86M |
SOPHiA GENETICS to Announce Financial Results for Second Quarter 2024 on August 6, 2024
BOSTON and ROLLE, Switzerland , July 23, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced it will release its financial results for the second quarter of fiscal year 2024...
India-Based Dhiti Omics is Now Live on SOPHiA DDM™
The diagnostics company has implemented the SOPHiA DDM™ Platform to enhance its solid tumor testing BOSTON and ROLLE, Switzerland , July 4, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced...
SOPHiA GENETICS Publishes Results of 2024 Annual General Meeting
BOSTON and ROLLE, Switzerland, June 24, 2024 (GLOBE NEWSWIRE) -- SOPHiA GENETICS SA (Nasdaq: SOPH), a healthcare technology company and a leader in data-driven medicine, is pleased to announce that its annual general meeting of shareholders (the “AGM”) was held...
SOPHiA GENETICS Launches New Residual Acute Myeloid (RAM) Application
Novel application supports measurable residual disease (MRD) testing to help monitor cancer and stay ahead of relapse BOSTON and ROLLE, Switzerland , June 24, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in...
SOPHiA GENETICS Announces Kepler Uniklinikum is Live on SOPHiA DDM™ Platform
The Hospital will use SOPHiA DDM™ to enhance its testing and research of blood cancers BOSTON and ROLLE, Switzerland , June 13, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a leader in data-driven medicine, today...
SOPHiA GENETICS Launches Global Consortium, SOPHiA UNITY, to Accelerate Cancer Research, Drug Development, and Data-Driven Patient Care
New collective intelligence network to enable the most advanced research in oncology in support of precision medicine BOSTON and ROLLE, Switzerland , May 30, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader...
SOPHiA GENETICS to Launch New Whole Genome Sequencing Capabilities
In collaboration with Microsoft and NVIDIA, SOPHiA GENETICS is developing a comprehensive whole genome analytical solution BOSTON and ROLLE, Switzerland , May 29, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven...
SOPHiA GENETICS Announces Instituto Mário Penna as New Customer
The hospital will enhance its testing and research of blood cancers with the SOPHiA DDM™ Platform BOSTON and ROLLE, Switzerland , May 20, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven...
Klinikum Klagenfurt am Wörthersee is Live with SOPHiA GENETICS
The SOPHiA DDM™ Platform will help broaden the hospital's cancer testing and diagnostic capabilities BOSTON and ROLLE, Switzerland , May 16, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced...
SOPHiA GENETICS SA (SOPH) Q1 2024 Earnings Call Transcript
SOPHiA GENETICS SA (NASDAQ:SOPH ) Q1 2024 Earnings Conference Call May 7, 2024 8:00 AM ET Company Participants Kellen Sanger - Head, Strategy and IR Jurgi Camblong - Co-Founder and CEO Ross Muken - CFO and COO Conference Call Participants...
Source: https://incomestatements.info
Category: Stock Reports